Few numbers attract regulatory scrutiny like an impurity limit. Set it too high and you invite a deficiency letter; set it too low and you burden every batch with an unachievable specification. The ICH Q3A(R2) and Q3B(R2) framework gives you a defensible ladder to climb — but only if you understand that the thresholds are dose-dependent, and that the ICH M7 mutagenicity overlay can override the whole scheme.
The three thresholds, tied to daily dose
ICH Q3A(R2) (drug substance) and Q3B(R2) (drug product) define three action thresholds for organic impurities and degradation products. Critically, they scale with the maximum daily dose — a high-dose product is held to tighter percentage limits:
Reporting threshold — the level at or above which an impurity must be reported (e.g. 0.05% for a drug substance at ≤2 g/day dose).
Identification threshold — the level at or above which you must structurally identify the impurity (e.g. 0.10% or 1.0 mg/day intake, whichever is lower).
Qualification threshold — the level at or above which you must establish biological safety (e.g. 0.15% or 1.0 mg/day intake, whichever is lower).
| Threshold | Drug substance (≤2 g/day) | Driven by |
|---|---|---|
| Reporting | 0.05% | Analytical capability |
| Identification | 0.10% or 1.0 mg/day | Structure |
| Qualification | 0.15% or 1.0 mg/day | Toxicology |
The design lesson is that these are not arbitrary percentages — they are a graded response in which the burden of proof rises with the level and the dose. Below reporting, you may stay silent; above qualification, you owe the assessor a safety argument.
Where ICH M7 changes the calculus
The Q3A/Q3B thresholds assume a non-mutagenic impurity. The moment an impurity carries a structural alert for mutagenicity, ICH M7(R2) takes precedence and the acceptable limit collapses from a fraction of a percent to the Threshold of Toxicological Concern — 1.5 µg/day — often orders of magnitude below the Q3A qualification threshold.
Screen every identified degradant for DNA-reactive alerts using a Q(SAR)-based assessment (statistical plus expert-rule methodologies).
Nitrosamines and the cohort of concern can fall even below the generic TTC, requiring compound-specific limits.
A "qualified" Q3B impurity is not automatically M7-clear — the two assessments answer different questions.
Don't forget the parallel Q3 family
Organic impurities are only one axis of the specification. A complete impurity control strategy also addresses:
ICH Q3C — residual solvents, with Class 1 (avoid), Class 2 (limit by PDE), and Class 3 (low-toxicity) categories.
ICH Q3D — elemental impurities, controlled to element-specific permitted daily exposures by route of administration.
ICH Q6A — the decision trees that tie these limits into the release and shelf-life specification.
Building a limit that survives review
An assessor rarely challenges the number itself; they challenge the justification. A defensible impurity limit rests on four pillars:
Origin — is it a process impurity or a degradation product? Degradants must be justified against real and predicted stability data.
Structure — an identified structure lets you run the M7 assessment and assign the correct threshold regime.
Safety — qualification data, read-across, or a toxicological rationale for anything above the qualification threshold.
Control — an analytical method genuinely capable of measuring at the reporting threshold, with the right relative response factors.
Process impurity or degradation product? The distinction sets the strategy
Q3A/Q3B treat the two differently, and conflating them is a common review finding. The control logic diverges at the source:
Process impurities are controlled upstream — in the route, the starting materials, and the drug-substance specification — and are typically constant batch to batch.
Degradation products grow over shelf life, so their limits must be justified against real-time and predicted stability, and they belong in the drug-product specification with a stability-indicating method behind them.
Quantifying either correctly depends on relative response factors: a UV detector that under-responds to an impurity will silently understate it, breaking both your mass balance and your limit justification.
The predictive advantage
The teams that clear impurity questions fastest are the ones that predicted the impurity list before it appeared. Knowing your degradation pathways in advance tells you which impurities to expect, which structures to pre-screen for mutagenicity, and therefore which threshold regime — Q3B percentage or M7 microgram — will govern each one. That foresight turns a reactive scramble into a pre-written justification.
Set impurity limits with confidence on the MolWard platform. Use the ICH Q3 Impurity Limits tool to derive dose-scaled reporting, identification and qualification thresholds; the ICH M7 Toxicology tool to screen degradants for mutagenic alerts and generate acceptable-intake limits; the PDE / Exposure Limits tool for Q3C/Q3D-style permitted daily exposures; and the Degradation Predictor to know which impurities to expect before your first stability pull.